Condition

Mucopolysaccharidosis Type 7

Find a Doctor

CW
Areas of Expertise

Chester B. Whitley

Fairview Express Care
Pediatrics, Medical Genetics
Male
Practicing approx. 41 years

Bio

Chester Whitley is a Pediatrics specialist and a Medical Genetics specialist in Minneapolis, Minnesota. Dr. Whitley is a global expert in Mucopolysaccharidosis Type 7. He has been an author on 96 peer reviewed articles and participated in 4 clinical trials in the past 15 years. In particular, he has been an author on 4 peer reviewed articles regarding Mucopolysaccharidosis Type 7. He is licensed to treat patients in MN.

Areas of Expertise

Contact

Minneapolis, MN 55414, US

612-672-7422

Latest Advances

Latest Advance
Study
  • Condition: Mucopolysaccharidosis VII
  • Journal: Molecular genetics and metabolism
  • Treatment Used: Vestronidase Alfa
  • Number of Patients: 12
  • Published —
This study examined the safety and effectiveness of vestronidase alfa therapy in patients with mucopolysaccharidosis VII.
Latest Advance
Study
  • Condition: Hurler Syndrome after Hematopoietic Cell Transplantation (HCT)
  • Journal: Pediatric research
  • Treatment Used: Laronidase
  • Number of Patients: 10
  • Published —
This study evaluated the effects of laronidase on somatic outcomes of patients with Mucopolysaccharidosis I (MPS IH) previously treated with hematopoietic cell transplantation (HCT).
Latest Advance
Study
  • Condition: Sanfilippo Syndrome Type A
  • Journal: Molecular genetics and metabolism
  • Treatment Used: Intrathecal Heparan-N-Sulfatase (HNS)
  • Number of Patients: 21
  • Published —
This study reported on the effectiveness , pharmacokinetics, safety, and tolerability of intrathecal (IT) administration of recombinant human heparan-N-sulfatase (rhHNS) in the treatment of Sanfilippo syndrome type A (mucopolysaccharidosis type IIIA), a lysosomal disorder associated with progressive neurodegeneration in early childhood.

Clinical Trials

Clinical Trial
  • Status: Recruiting
  • Participants: 40
  • Start Date: June 12, 2020
Natural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) Patients
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Biological
  • Participants: 30
  • Start Date: July 23, 2019
A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, a rAAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 4
  • Intervention Type: Other, Drug
  • Participants: 30
  • Start Date: December 22, 2015
Synergistic Enteral Regimen for Treatment of the Gangliosidoses (Syner-G)
Clinical Trial
  • Status: Recruiting
  • Participants: 200
  • Start Date: July 2005
MPS VI Clinical Surveillance Program (CSP)

All Publications
View All

Publication
Study
  • Journal: Molecular genetics and metabolism reports
  • Published —
The juvenile gangliosidoses: A timeline of clinical change.
Publication
Study
  • Journal: Molecular genetics and metabolism
  • Published —
Corrigendum to "The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII" [Mol Genet Metab 2020 Mar;129(3):219-227].

Contact

Minneapolis, MN 55414, US

612-672-7422

Affiliations

  • University Of Minnesota Medical Center, Fairview

Credentials

  • Graduate InstitutionUniversity Of Minnesota Medical School
    1980
  • Licenses
    Clinical Genetics in MN
  • Board Certifications
    Pediatric Medicine

Insurance

Contact them to find out if they accept your insurance plan.